Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Evaluation of clofazimine treatment on functional gene transcription in hepatocellular carcinoma cells

ABSTRACT: Clofazimine (CFZ) is an orally administered anti-mycobacterial drug that demonstrates a broad spectrum of activity against mycobacterial infections, including leprosy and tuberculosis. CFZ also possesses anti-inflammatory and anti-tumor properties by disrupting DNA replication and inhibiting the production of IL2. Currently, this compound has been utilized in research related to drug-resistant cancer treatment, and has gained increasing recognition for its potential to enhance cancer treatment in recent years. Considering the benefits of CFZ in clinical settings, it presents itself as a promising candidate for combination drug therapy aimed at hepatocellular carcinoma through the regulation of functional gene transcription. Herein, we primarily examine the role of CFZ treatment throughout the functional gene transcription process in hepatocellular carcinoma cells.

ORGANISM(S): Homo sapiens

PROVIDER: GSE327600 | GEO | 2026/04/15

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Clofazimine is a broad-spectrum coronavirus inhibitor that antagonizes SARS-CoV-2 replication in primary human cell culture and hamsters

Project description:COVID-19 is the third outbreak of zoonotic coronavirus (CoV) of the century after the epidemic Severe acute respiratory syndrome CoV (SARS-CoV) in 2003 and Middle East respiratory syndrome CoV (MERS-CoV) in 2012. Treatment options for CoVs are largely lacking. Here, we show that clofazimine, an anti-leprosy drug with favorable safety and pharmacokinetics profile, possesses pan-coronaviral inhibitory activity, and can antagonize SARS-CoV-2 replication in multiple in vitro systems, including the human embryonic stem cell-derived cardiomyocytes and ex vivo lung cultures. The FDA-approved molecule was found to inhibit multiple steps of viral replication, suggesting polypharmacology is likely underlying its antiviral activity. In a hamster model of SARS-CoV-2 pathogenesis, prophylactic and therapeutic administration of clofazimine significantly reduced lung viral load and fecal viral shedding, as well as reversal of cytokine storm. Additionally, clofazimine exhibited antiviral drug synergy when administered with remdesivir. Since clofazimine is orally bioavailable and has a comparatively low manufacturing cost, it is an attractive clinical candidate for outpatient treatment and remdesivir-based combinatorial therapy for hospitalized COVID-19 patients, particularly in developing countries. Taken together, our data provide evidence that clofazimine may prove effective against current pandemic SARS-CoV-2, endemic MERS-CoV in the Middle East, and, possibly most importantly, emerging CoV of the future.

2021-02-02 | GSE162899 | GEO

Inhibition of the Aryl Hydrocarbon Receptor - Polyamine Biosynthesis Axis Suppresses Multiple Myeloma and prostate cancer progression

Project description:Polyamine inhibition for cancer therapy is, conceptually, an attractive approach but has yet to meet success in the clinical setting. The aryl hydrocarbon receptor (AHR) is the central transcriptional regulator of xenobiotic response. Our study revealed that AHR also positively regulated intracellular polyamine production via direct transcriptional activation of two genes (ODC1 and AZIN1) involved in polyamine biosynthesis and control, respectively. In multiple myeloma patients, AHR levels inversely correlated with survival, suggesting that AHR inhibition may be beneficial for treatment of this disease .We identified clofazimine, an FDA-approved anti-leprosy drug, as a potent AHR antagonist and a suppressor of polyamine biosynthesis. Experiments in a transgenic model of multiple myeloma (Vk*Myc mice) and in immunocompromised mice bearing multiple myeloma cell xenografts, revealed high efficacy of clofazimine comparable to that of bortezomib, a first-in-class proteasome inhibitor used for treatment of multiple myeloma. This study identified a previously unrecognized regulatory axis between AHR and polyamine metabolism and discovered clofazimine as an inhibitor of AHR and a potentially clinically-relevant anti-multiple myeloma agent. RNA-seq: human multiple myeloma MM1S and human normal fibroblasts WI38 cells -/+ CLF 2-4uM for 24hrs; -/+ shAHR

2018-07-18 | GSE117160 | GEO

Evaluation of clofazimine treatment on functional gene transcription in hepatocellular carcinoma cells

Project description:Evaluation of clofazimine treatment on functional gene transcription in hepatocellular carcinoma cells

| PRJNA1451517 | ENA

Ancient palaeoimmunology: diving deeper with a two enzyme proteomics approach

Project description:This study investigates the efficacy of proteomic analysis of human remains to identify active Mycobacterium leprae infections in the past. Mycobacterial diseases, like leprosy, have plagued human populations for millennia. Thanks to effective treatment options, leprosy is not as widespread and deadly as in the past, yet remains endemic in certain regions with increasing concerns of strains becoming resistant to antibiotic treatments. We present a dual-enzyme, optimised extraction protocol, using trypsin and ProAlanase, to increase the recovery of non-collagenous proteins through a study of five individuals from a Mediaeval leprosarium cemetery, as well as four from a non-leprosy associated cemetery. Here we show that skeletal samples from the leprosarium individuals contain numerous immune proteins associated with modern leprosy, while those from a non-leprosy associated cemetery do not. Through this study, we advance a palaeoimmunology methodology and provide insights into the health of archaeological individuals and offer a means to triage samples for aDNA analysis.

2024-05-24 | PXD040419 | Pride

Multiplexed transcriptomics to screen drug combination and define therapeutic mechanism of action at single-cell resolution

Project description:Compared to classical drug screening, single-cell screening not only significantly enhances throughput but also provides richer transcriptional response information. In this study, we employed the high-throughput single-cell sequencing technology, snHH-seq, to screen clinical drug combinations with anti-hepatocellular carcinoma activity. Single-cell transcriptomics revealed that the combination of HHT and YM155 (HY) exhibited the most potent inhibitory effect on cellular proliferation, which was also validated through in vitro and in vivo functional assays. Mechanistically, transcription factor regulatory network analysis identified cell type-specific regulators in each subpopulation with HY treatment, and revealed that the anticancer effects primarily target apoptosis-related subpopulations. These findings provide critical insights for precision diagnosis and treatment of hepatocellular carcinoma.

2026-05-28 | GSE291757 | GEO

A quadrivalent in vivo CAR-macrophage repress solid tumors and overcome tumor heterogeneity through antigen spreading

Project description:We designed a quadrivalent in vivo CAR-engineered macrophage based on the LNP-mRNA system, delivering FAP CAR-ΔTGFβRII and GPC3 CAR-Super IL2 (LNP-GF CAR) via LNP for the treatment of primary hepatocellular carcinoma. LNP-GF CAR demonstrated significant anti-tumor efficacy in a primary hepatocellular carcinoma mouse model. To further dissect the anti-tumor mechanism of LNP-GF CAR, we performed single-cell transcriptomic sequencing on tumor regions of the liver from treated model mice. Based on the single-cell transcriptomic data, we found that exogenous CAR mRNA was highly enriched in tissue-resident macrophages within the liver tumor regions. CAR-expressing macrophages showed significant upregulation of genes related to antigen cross-presentation and promotion of T cell activation and proliferation. Consistently, the numbers of proliferative and activated CD8 T cells were significantly increased. These findings provide further evidence that in situ CAR macrophages can activate CD8 T cells through antigen cross-presentation, and deepen our understanding of the anti-tumor mechanism of LNP-GF CAR.

2026-05-16 | GSE330648 | GEO

Transcriptional profiling of Mycobacterium tuberculosis exposed to antibiotic treatment in broth culture.

Project description:We profiled Mtb transcriptional response to a range of different antibiotic drug exposures in 7H9 broth culture by RNA-seq. Compound abbreviations: (AMK = amikacin, BDQ = bedaquiline, CPF = ciprofloxacin, LVF = levofloxacin, MXF = moxifloxacin, CFZ = clofazimine, PA824 = pretomanid, RPE = rifapentine, PZA = pyrazinamide). We also hypothesized that an improved Mycobacterium tuberculosis (Mtb) transcriptional regulatory network (TRN) could be inferred using a large, diverse compendium of RNA-seq data and therefore sought to supplement the existing repository of Mtb expression data available on SRA with additional conditions that could inform on Mtb's underlying regulatory programs. We went on to infer Mtb's TRN using a collection of inference methods in combination with this compendium, and employed it to build an interpretable machine learning model of Mtb fitness under stress.

2025-03-19 | GSE292332 | GEO

TGFb dependent Treg conversion and the inhibition of conversion by IL6

Project description:Analysis of CD4+ cells activated with anti-CD3 and cultured in the presence of IL2. The effects of TGFb and IL6 on Treg conversion were analyzed to discover methods of inhibiting Treg conversion and/or Treg functional inhibition. CD4+ T-cells were enriched from lymph nodes of Foxp3-GFP mice and cultured under the under the following conditions: 1) anti-CD3+IL2; 2) anti-CD3+IL2+TGFÎ²; 3) anti-CD3+IL2+TGFÎ²+IL6; and 4) anti-CD3+IL2+IL6. On day 4 cells were collected, stained with anti-CD4-PE, and sorted into CD4+FOXP3- and CD4+FOXP3+ populations (>95% purity). For each treatment condition T-effector cells and Tregs were labeled independently (either cy3 or cy5) and hybridized together for a two-color array experiment. Each treatment condition had dye swapped replicates, and a minimum of 3 replicate in total. Two color experiment. Four conditions : 1) anti-CD3+IL2, 3 samples 2) anti-CD3+IL2+TGFÎ², 3 samples 3) anti-CD3+IL2+TGFÎ²+IL6, 4 samples 4) anti-CD3+IL2+IL6, 3 samples

2010-04-07 | E-GEOD-21027 | biostudies-arrayexpress

Genome-wide expression profiling of leprosy and granuloma annulare skin lesions

Project description:Here we report the data generated by short-read sequencing of mRNA (polyA) isolated from granuloma annulare and leprosy skin lesions. Our main aim was to identify putative mRNA biomarkers for distinguishing leprosy from other differential diagnoses. Additionally, we also explored the distinction between MB and PB by using differential expression analysis as well as training a penalized logistic regression to select important features. Our results showed that few genes are enough to differentiate leprosy lesions, including paucibacillary cases, from other morphological and histopathological similar skin diseases. Some of these genes have been replicated in a larger and more heterogeneous sample with RT-qPCR, validating their classification potential. We also suggest important novel gene candidates to improve our understanding of molecular differences between MB and PB lesions, which could either pinpoint new pathways and targets for host-based specialized adjuvant treatment for leprosy. Finally, this dataset has been used to explore the relationship between cornification and keratinocyte-related genes and TGFB-mediated epithelial-mesenchymal transition (EMT), which could indicate that in skin, M. leprae could be de-differentiating, directly or indirectly, other cell types into a progenitor/stem-like phenotype, facilitating mycobacterial survival and migration within the host. Alternatively, this could highlight which pathways are activated during granuloma formation and/or skin barrier assembly/disassembly.

2021-10-01 | E-MTAB-10318 | biostudies-arrayexpress

Comparison of the gene expression profiles of carfilzomib-resistant derivatives versus parental human myeloma cell lines

Project description:KMS-11 and KMS-34 cells were exposed to stepwise increasing concentrations of carfilzomib over a period of 18 weeks: cells adapted to growth in 4 nM carfilzomib by 4 weeks, in 6 nM in another 6 weeks and in 12 nM after a further 8 weeks. The resulting cell cultures, denoted KMS-11/Cfz and KMS-34/Cfz, respectively, retained resistance to carfilzomib even when tested after removal of selective pressure for approximately 8 weeks. KMS-11/Cfz and KMS-34/Cfz cells were profiled for gene expression after 1 week of growth in the absence of carfilzomib together with parental KMS-11 and KMS-34 cells which had not been selected in the drug (triplicate samples).

2015-07-09 | E-GEOD-69078 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data